Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04270019
Other study ID # 0644
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date June 26, 2020
Est. completion date September 15, 2023

Study information

Verified date January 2024
Source Nova Scotia Health Authority
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PEG is a fusogen, a type of chemical that aids in mediating cell fusion. PEG helps nerve cells recover neuronal continuity by removing plasmalemmal-bound water which opens the axonal ends on both sides of the injury. Opening axonal ends permits the nerve ends to reconnect and begin regeneration. PEG has been tested on animal models extensively and in earthworm models has been shown to induce fusion rates in 80-100% of neuronal cells. In crushed or severed mammalian sciatic nerves PEG has enhanced neuronal continuity to baseline functioning levels. Human applications for PEG have been tested by Bamba and colleagues in a case series with encouraging results. No studies, to our knowledge, have prospectively examined the use of PEG in peripheral nerve injuries. We propose a placebo controlled, double-blinded randomized controlled trial to test the hypothesis that local PEG administration can enhance sensory nerve regeneration following digital nerve transection compared to surgery alone.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 15, 2023
Est. primary completion date September 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years to 120 Years
Eligibility Inclusion Criteria: - (1) surgery within twenty-four hours of injury (2) surgery completed in the minor procedures unit of the Halifax Infirmary. Exclusion Criteria: - (1) patients with cognitive impairment

Study Design


Intervention

Drug:
Polyethylene Glycol 3350
In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
Normal Saline
Standard solution of sterile normal saline.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Nova Scotia Health Authority

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Sensory Recovery Sensory recovery will be assessed by a blinded and trained OT through standardized testing with static two point discrimination (s2PD) and Semmes-Weinstein monofilament testing (SWMT). The end point will be composite in nature as both s2PD and SWMT are important to gauge and are the gold standards in determining sensory recovery. Testing to be done at one month, three months, and six months post-operatively.
Secondary Functional Recovery Functional recovery assessed by the Michigan Health Questionnaire (MHQ). Administered six months post-operatively. Maximum score of 100, minimum score of 0. A higher score means better functional recovery.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01437332 - Molecular Mediators of Nerve Injury Signaling N/A
Completed NCT03624426 - Detection and Prevention of Nerve Injury in Shoulder Arthroplasty Surgery N/A
Recruiting NCT04662320 - Promoting Healing Of Nerves Through Electrical Stimulation N/A
Recruiting NCT04144972 - Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain N/A
Completed NCT02960516 - MRI Diffusion Tensor Tractography to Monitor Peripheral Nerve Recovery After Severe Crush or Cut/Repair Nerve Injury
Completed NCT05589324 - Effects of 3D Printing Writing Assisitive Device on Feasibility in Patients With Nerve Injury
Recruiting NCT03970161 - Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy N/A
Completed NCT01533337 - Free Dorsal Digital Flap for Reconstruction of Volar Soft Tissue Defect of Digits N/A
Completed NCT01528397 - Reconstruction of Proper Digital Nerve Defects in the Thumb Using a Pedicled Nerve Graft N/A
Enrolling by invitation NCT05080608 - Nerve Injury in the Hand, an Interview Study
Completed NCT03881462 - Deltoid Muscle Contribution to Shoulder Function N/A
Completed NCT05302141 - Effects of Assistive Device on ADL Function in Patients With Nerve Injury N/A
Terminated NCT01751503 - Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer N/A
Recruiting NCT05365282 - Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study
Active, not recruiting NCT03701581 - 4-aminopyridine Treatment for Nerve Injury Phase 2/Phase 3
Completed NCT04420689 - A Study of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery Phase 1/Phase 2
Recruiting NCT05884125 - Promoting Healing of Injured Nerves With Electrical Stimulation Therapy N/A
Recruiting NCT05611983 - Experience and Feasibility of Methods for Early Sensory Training N/A
Completed NCT02032030 - Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys
Completed NCT03701685 - A Comparison of the Littler Flap With the Bipedicled Nerve Flap N/A